Greenleaf Trust Reduces Position in Illumina, Inc. (NASDAQ:ILMN)

Greenleaf Trust lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMNGet Rating) by 13.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,421 shares of the life sciences company’s stock after selling 661 shares during the quarter. Greenleaf Trust’s holdings in Illumina were worth $815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Illumina by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 12,425,305 shares of the life sciences company’s stock valued at $4,341,402,000 after purchasing an additional 225,783 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Illumina by 5.4% during the 2nd quarter. Loomis Sayles & Co. L P now owns 3,732,098 shares of the life sciences company’s stock valued at $688,050,000 after purchasing an additional 191,341 shares during the period. Invesco Ltd. raised its position in shares of Illumina by 6.4% during the 1st quarter. Invesco Ltd. now owns 1,760,727 shares of the life sciences company’s stock valued at $615,199,000 after purchasing an additional 105,347 shares during the period. Veritas Asset Management LLP raised its position in shares of Illumina by 150.6% during the 2nd quarter. Veritas Asset Management LLP now owns 1,563,455 shares of the life sciences company’s stock valued at $288,239,000 after purchasing an additional 939,671 shares during the period. Finally, Sustainable Growth Advisers LP raised its position in shares of Illumina by 18.1% during the 1st quarter. Sustainable Growth Advisers LP now owns 1,176,193 shares of the life sciences company’s stock valued at $410,962,000 after purchasing an additional 180,412 shares during the period. Hedge funds and other institutional investors own 86.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ILMN. Piper Sandler reduced their price target on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a report on Monday, November 14th. Citigroup reduced their price target on shares of Illumina from $220.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, August 12th. UBS Group reduced their price target on shares of Illumina from $350.00 to $245.00 and set a “neutral” rating on the stock in a report on Wednesday, August 17th. Robert W. Baird reduced their price target on shares of Illumina from $215.00 to $210.00 in a report on Friday, November 4th. Finally, Atlantic Securities reduced their price target on shares of Illumina to $190.00 in a report on Monday, August 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $254.38.

Illumina Price Performance

ILMN stock opened at $222.08 on Thursday. Illumina, Inc. has a 12 month low of $173.45 and a 12 month high of $428.00. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $211.93 and a 200 day moving average price of $211.15. The stock has a market cap of $34.93 billion, a PE ratio of -8.41 and a beta of 1.17.

Insider Buying and Selling

In related news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $223.65, for a total transaction of $111,825.00. Following the completion of the transaction, the senior vice president now directly owns 40,112 shares of the company’s stock, valued at approximately $8,971,048.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Further Reading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.